MedTrace Logo

Study on the Bioavailability of SHR0302 in Healthy Subjects

NCT04712838 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-10-20

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, and the relative bioavailability of SHR0302 tablets with three different formulations in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

SHR0302

Group A subjects were given oral F1 、F2 and F3 version SHR0302

DRUG

SHR0302

Group B subjects were given oral F1 、F3 and F2 version SHR0302

DRUG

SHR0302

Group C subjects were given oral F2 、F1 and F3 version SHR0302

DRUG

SHR0302

Group D subjects were given oral F2 、F3 and F1 version SHR0302

DRUG

SHR0302

Group E subjects were given oral F3 、F1 and F2 version SHR0302

DRUG

SHR0302

Group F subjects were given oral F3 、F2 and F1 version SHR0302

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2021-04-13
Completion
2021-04-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04712838 on ClinicalTrials.gov